Saturday 7 November 2026 Export TRAW’s income statement to Excel — free account

Traws Pharma, Inc.

TRAW Healthcare Biotechnology

Traws Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.8 million, up 1,134.5% from fiscal 2024.

Revenue: −100.0%
EPS: −45.5%
Free cash flow: −25.5%

Quarter to June 2026, against a year earlier

Insider buying

0.23 0.01 +4.55%

Follow TRAW

Alert me

Market cap: $3.4M
P/E: 0.0×
Fwd P/E: −0.3×
Dividend yield: —
F-score: 4/9
Altman Z: −89.55
Beneish M: 2517.31
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Bought, $m 1.00

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	1	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 31.54%

Capital & Financial Ratios $m

Size

Market Cap 3.38

Revenue ttm 2.85

Net income ttm (21.57)

Free cash flow ttm (16.85)

Net debt Q (5.02)

Valuation

P/E 0.00

Forward P/E (0.25)

Price / sales 1.28

Forward P/S Powerpack

Price / FCF 0.00

Price / book 2.16

Financial health

Current ratio Q 0.93

Debt / equity Q 0.00

Interest coverage Q 0.00

Growth

Revenue growth Q −100.00%

Operating income growth Q −154.20%

EPS, this year −246.34%

EPS, next year A −2.92%

Revenue, next year A +369.53%

EPS, past 5 yrs —

EPS, next 5 yrs A +56.00%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 9.75%

10-year low 10-year high

P/B against its own 10 years 56.25%

10-year low 10-year high

EV/FCF against its own 10 years 14.63%

10-year low 10-year high

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	21	21	4	5
Receivables	0	2	4	3
Inventory	—	—	—	—
Other	—	—	—	—
	23	25	8	9

	2023	2024	2025	Q'26
Payables	6	8	6	6
ST’ Debt	—	—	—	—
Other	—	—	—	—
	9	12	11	10

Compound Annual Growth %

	10y	5y	3y
Sales	(13.17%)	64.59%	131.12%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.22 Actual −0.16

−10.11 −7.30 −4.48 −1.67 1.14

Q1 FY24 Met 0.00

Q3 FY24 Miss −2.56

Q1 FY26 Beat +0.39

Q2 FY26 Beat +0.06

Q3 FY26 — Nov 12

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q1 FY24	−6.00	−6.00	Met by 0.00
Q3 FY24	−6.25	−8.81	Miss by 2.56
Q1 FY26	−0.92	−0.53	Beat by 0.39
Q2 FY26	−0.22	−0.16	Beat by 0.06
Q3 FY26	−0.21	—	Reports 12 November 2026

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.53)	(0.16)	—	—	—
’25	2.09	(0.11)	(0.34)	(0.48)	0.82
’24	(6.00)	(121.75)	(1.49)	(6.31)	(35.21)
’23	(7.00)	(5.00)	(5.75)	(5.00)	(22.50)
’22	(5.00)	(4.75)	(6.50)	(6.50)	(22.75)
’21	(7.50)	(6.75)	(5.50)	(4.00)	(24.00)
’20	(11.24)	(14.99)	(11.24)	(11.24)	(52.47)

Fiscal quarters ending in the months shown.

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	0	3	—	0	3
’24	0	0	0	0	0
’23	0	0	0	0	0
’22	0	0	0	0	0
’21	0	0	0	0	0
’20	0	0	0	0	0

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(8)	—	—	—
’25	(5)	(6)	(4)	(3)	(18)
’24	(4)	(10)	(11)	(4)	(30)
’23	(5)	(4)	(4)	(4)	(18)
’22	(4)	(4)	(4)	(4)	(16)
’21	(7)	(4)	(4)	(4)	(19)
’20	(6)	(5)	(6)	(5)	(23)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(3)	(8)	—	—	—
’25	(5)	(6)	(7)	(3)	(21)
’24	(4)	(10)	(11)	(4)	(30)
’23	(5)	(4)	(4)	(4)	(18)
’22	(4)	(4)	(4)	(4)	(16)
’21	(7)	(4)	(4)	(4)	(19)
’20	(6)	(5)	(6)	(5)	(23)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	6	1	1	2	0	0	0	0	0	3	3		(7.3%)	13	13	55	+170.8%
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00		0.0 pt	Powerpack Traws Pharma, Inc.’s next three years, line by line Analysts expect revenue to grow 170.8% a year to 2028 — faster than the −7.3% of the last 9 years. See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	(20)	(24)	(21)	(21)	(25)	(16)	(19)	(19)	(167)	9	(22)		n/m
	EBT margin, %	(354.36)	(3,059.59)	(1,672.15)	(984.56)	(10,888.74)	(7,151.77)	(8,391.15)	(8,384.07)	(73,682.74)	328.67	0.00		+683.0 pt
	Net income	(20)	(24)	(20)	(22)	(25)	(16)	(19)	(19)	(167)	9	(22)		n/m
Per share, $
Per share, $	Revenue	6,932.50	491.88	111.64	56.85	0.50	0.34	0.27	0.27	0.15	0.34	0.00		(66.8%)
	Earnings	(24,937.58)	(15,052.41)	(1,870.31)	(558.47)	(52.47)	(24.00)	(22.75)	(22.50)	(35.21)	0.83	(1.51)		n/m
	Cash flow	(19,766.25)	(14,887.50)	(2,063.27)	(542.47)	(49.72)	(28.94)	(19.48)	(21.36)	(19.19)	(2.21)	(1.06)		(63.6%)
	Capex	0.00	0.00	0.00	(1.43)	(0.03)	0.00	0.00	(0.02)	0.00	(0.31)	0.00		n/m
	Free cash flow	(19,766.25)	(14,887.50)	(2,063.27)	(543.91)	(49.75)	(28.94)	(19.48)	(21.37)	(19.19)	(2.52)	(1.06)		(63.1%)
	Book value	6,408.75	(6,788.12)	489.73	301.41	13.31	68.50	33.85	12.71	(20.37)	(0.08)	0.11		n/m
	Shares, m	0	0	0	0	0	1	1	1	2	8	11		+179.1%
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.91	0.00		0.1
	P/S	1.80	17.15	7.09	2.53	350.93	189.92	65.68	73.37	61.01	3.27	1.28		77.3
	P/B	1.95	0.00	1.62	0.48	13.13	0.93	0.52	1.55	0.00	0.00	2.16		2.0
	EV/Sales	(2.07)	12.04	(6.73)	(7.88)	268.57	(53.75)	(105.81)	(18.76)	(33.41)	1.92	(0.48)		5.4
	EV/FCF	0.71	(0.39)	0.36	0.82	(2.69)	0.62	1.47	0.24	0.25	(0.30)	0.08		0.1
Cash, $m
Cash, $m	Operating cash flow	(16)	(24)	(23)	(21)	(23)	(19)	(16)	(18)	(30)	(18)	(17)		+1.6%
	Capex	—	—	—	0	0	—	—	0	—	(3)	0		+90.0%
	Free cash flow	(16)	(24)	(23)	(21)	(23)	(19)	(16)	(18)	(30)	(21)	(17)		+3.1%
Balance, $m
Balance, $m	Working capital	13	(5)	9	15	10	49	31	13	13	(3)	(1)		n/m
	Net debt	(21)	(4)	(17)	(23)	(19)	(55)	(39)	(21)	(21)	(4)	(5)		(17.4%)
	Shareholders’ equity	5	(11)	5	12	6	46	28	11	(32)	(1)	2		n/m
Returns, %
Returns, %	ROA	(84.27)	(170.79)	(179.66)	(103.39)	(115.24)	(42.84)	(39.99)	(61.07)	(229.51)	38.59	(123.55)		+122.9 pt
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		0.0 pt
	ROE	(246.35)	840.32	751.66	(253.56)	(283.48)	(61.81)	(50.96)	(97.22)	521.75	(42.56)	(336.30)		+203.8 pt
People
People	Employees	23	25	25	19	12	15	17	17	7	7	—		(12.4%)
	Revenue/emp, $m	0.24	0.03	0.05	0.11	0.02	0.02	0.01	0.01	0.03	0.40	—		+5.7%

Negative figures in brackets.

estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Dec 2025 · fundamentals updated 26 Oct 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CVKD Cadrenal Therapeutics, Inc.	$3.6M	— (loss-making)	—	—	n/m	+26.24% (above 0%: growing)	0.00%	0.00%	Compare
LIMN Liminatus Pharma Inc.	$3.5M	— (loss-making)	—	—	n/m	+89.00% (above 0%: growing)	—	0.00%	Compare
GRI GRI Bio, Inc.	$3.4M	— (loss-making)	— (loss-making)	—	n/m	+54.33% (above 0%: growing)	0.00%	0.00%	Compare
LIPO Lipella Pharmaceuticals Inc.	$3.4M	— (loss-making)	— (loss-making)	−36.44% (below 0%: shrinking)	n/m	−41.79% (below 0%: shrinking)	100.00%	0.00%	Compare
TRAW Traws Pharma, Inc.	$3.4M	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	−25.51% (below 0%: shrinking)	0.00%	0.00%
PBLA Panbela Therapeutics Inc.	$3.4M	— (loss-making)	—	—	n/m	+66.23% (above 0%: growing)	—	0.00%	Compare
ONCO Onconetix, Inc.	$3.2M	— (loss-making)	— (loss-making)	−83.94% (below 0%: shrinking)	n/m	−36.00% (below 0%: shrinking)	25.15%	(15,969.59%)	Compare
SXTP 60 Degrees Pharmaceuticals Inc.	$3.2M	— (loss-making)	— (loss-making)	−32.48% (below 0%: shrinking)	n/m	−54.33% (below 0%: shrinking)	27.32%	(1,092.40%)	Compare
ADXN Addex Therapeutics Ltd. Sponsored ADR	$3.1M	— (loss-making)	— (loss-making)	−85.95% (below 0%: shrinking)	n/m	−2.73% (below 0%: shrinking)	(2.67%)	0.00%	Compare
Median of peers	$3.4M	—	—	−60.19%	—	+11.76%	12.58%	0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 20 October 2026

Ownership

Directors and executive officers, together 8.73%

OrbiMed Advisors LLC 11.70%

Entities affiliated with Sirenia Capital Management 9.99%

Ikarian Healthcare Master Fund, L.P. 9.45%

Ally Bridge Medalpha Master Fund L.P. 7.59%

Perceptive Advisors LLC 5.99%

Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Traws Pharma, Inc. (TRAW) Latest News

14 Aug

Impact 4 · 7:00 AM · GlobeNewswire

Traws Pharma Reports Second Quarter 2025 Results and Business Highlights

Impact 3 · 4:30 PM

Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights

22 Jun

Impact 3 · 7:00 AM · GlobeNewswire

Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program

15 Jun

Impact 3 · 6:26 AM · InvestorsHub

Traws Pharma Shares Slide After UK Regulator Postpones Influenza Study

12 Jun

Impact 4 · 8:07 PM · Stocktwits

Why Did TRAW Stock Slump 28% After Hours?

Impact 3 · 5:30 PM

Traws Pharma Provides Regulatory Update on Influenza Program

27 May

Impact 4 · 8:45 AM · GlobeNewswire

Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks

Impact 4 · 8:00 AM · GlobeNewswire

Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness

15 May

Impact 4 · 7:00 AM

Traws Pharma Reports First Quarter 2025 Results and Business Highlights

Impact 3 · 7:00 AM · GlobeNewswire

Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results

8 May

Impact 4 · 7:30 AM · GlobeNewswire

Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections

16 Apr

Impact 4 · 8:30 AM · Moby

Traws Pharma, Inc. Q4 2025 Earnings Call Summary

Impact 4 · 3:01 AM · GuruFocus.com

Traws Pharma Inc (TRAW) Q4 2025 Earnings Call Highlights: A Turnaround Year with Significant ...

15 Apr

Impact 4 · 4:01 PM · GlobeNewswire

Traws Pharma Reports Full Year 2025 Results and Provides Business Highlights

Impact 4 · 8:15 AM · GlobeNewswire

Traws Pharma Announces Up to $60 Million Private Placement Financing

19 Feb

Impact 4 · 7:30 AM · GlobeNewswire

Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

26 Jan

Impact 4 · 8:30 AM · GlobeNewswire

Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza

13 Jan

Impact 4 · 7:00 AM · GlobeNewswire

Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients

22 Dec

Impact 3 · 8:01 AM

TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors

17 Dec

Impact 4 · 6:00 AM

Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients

13 Nov

Impact 4 · 7:00 AM

Traws Pharma Reports Third Quarter 2025 Results and Business Highlights

30 Oct

Impact 4 · 12:00 PM · PR Newswire

ChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical Trials

22 Oct

Impact 4 · 6:40 PM · PR Newswire

Dover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.

14 Oct

Impact 4 · 7:00 AM · GlobeNewswire

Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025

6 Oct

Impact 3 · 7:00 AM · GlobeNewswire

Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives

25 Sep

Impact 3 · 7:30 AM · GlobeNewswire

Annovis Appoints Mark Guerin as Chief Financial Officer

18 Aug

Impact 4 · 7:00 AM

Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025

30 Jun

Impact 4 · 6:30 AM · GlobeNewswire

Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions

3 Jun

Impact 4 · 7:00 AM · GlobeNewswire

Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib

31 Mar

Impact 4 · 9:00 AM · GlobeNewswire

Traws Pharma Reports Full Year 2024 Results and Business Highlights

Insider Decisions last twelve months

Capital & Financial Ratios $m

Valuation vs history

Dividends

Assets vs Liabilities $m

Compound Annual Growth %

Earnings Trends EPS, adjusted, against the consensus

EPS $

Revenue $m

Operating Cash Flow $m

Free Cash Flow $m

Target Price Range

Recommendation Rating

Ten years at a glance Fiscal years to December

Traws Pharma, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Pay and ownership Proxy statement filed 20 October 2026

Ownership

Traws Pharma, Inc. (TRAW) Latest News

14 Aug

22 Jun

15 Jun

12 Jun

27 May

15 May

8 May

16 Apr

15 Apr

19 Feb

26 Jan

13 Jan

22 Dec

17 Dec

13 Nov

30 Oct

22 Oct

14 Oct

6 Oct

25 Sep

18 Aug

30 Jun

3 Jun

31 Mar

Stockrow Weekly